REGN 846

Drug Profile

REGN 846

Alternative Names: R846; REGN846; SAR 302532

Latest Information Update: 22 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis

Most Recent Events

  • 06 Aug 2013 Discontinued - Phase-I for Atopic dermatitis in Australia (IV)
  • 06 Aug 2013 Discontinued - Phase-I/II for Atopic dermatitis in Finland , Germany and Poland (IV)
  • 06 Aug 2013 Discontinued - Phase-II for Atopic dermatitis (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top